{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:38:03Z","timestamp":1781617083036,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"DOI":"10.7759\/cureus.101340","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:24:07Z","timestamp":1768220647000},"source":"Crossref","is-referenced-by-count":1,"title":["Current and Emerging Strategies for the Prevention of Respiratory Syncytial Virus (RSV) Infections: A Comprehensive Review of Vaccines and Antibody Therapies"],"prefix":"10.7759","author":[{"given":"Diana","family":"Genis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajhat","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2011.09.020","article-title":"Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years","volume":"162","author":"Collins PL","year":"2011","unstructured":"Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011, 162:80-99. 10.1016\/j.virusres.2011.09.020","journal-title":"Virus Res"},{"key":"ref2","article-title":"Respiratory syncytial virus infection in children","author":"Chamarthi S","year":"2025","unstructured":"Chamarthi S, Chamarthi VS, Daley SF. Respiratory syncytial virus infection in children. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref3","unstructured":"Surveillance of RSV. (2025). Accessed. November 20, 2025: https:\/\/www.cdc.gov\/rsv\/php\/surveillance\/index.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.53854\/liim-3204-6","article-title":"RSV vaccination as the optimal prevention strategy for older adults","volume":"32","author":"Andreoni M","year":"2024","unstructured":"Andreoni M, Bonanni P, Gabutti G, Maggi S, Siliquini R, Ungar A. RSV vaccination as the optimal prevention strategy for older adults. Infez Med. 2024, 32:478-88. 10.53854\/liim-3204-6","journal-title":"Infez Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36342","article-title":"Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation","volume":"15","author":"Kaler J","year":"2023","unstructured":"Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 2023, 15:e36342. 10.7759\/cureus.36342","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur NI","year":"2023","unstructured":"Mazur NI, Terstappen J, Baral R, et al.. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023, 23:e2-e21. 10.1016\/S1473-3099(22)00291-2","journal-title":"Lancet Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01012-2","article-title":"Differences between RSV\u00a0A and RSV\u00a0B subgroups and implications for pharmaceutical preventive measures","volume":"13","author":"Nuttens C","year":"2024","unstructured":"Nuttens C, Moyersoen J, Curcio D, et al.. Differences between RSV\u00a0A and RSV\u00a0B subgroups and implications for pharmaceutical preventive measures. Infect Dis Ther. 2024, 13:1725-42. 10.1007\/s40121-024-01012-2","journal-title":"Infect Dis Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan JS","year":"2011","unstructured":"McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011, 85:7788-96. 10.1128\/JVI.00555-11","journal-title":"J Virol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens8020067","article-title":"A contemporary view of respiratory syncytial virus (RSV) biology and strain-specific differences","volume":"8","author":"Pandya MC","year":"2019","unstructured":"Pandya MC, Callahan SM, Savchenko KG, Stobart CC. A contemporary view of respiratory syncytial virus (RSV) biology and strain-specific differences. Pathogens. 2019, 8:10.3390\/pathogens8020067","journal-title":"Pathogens"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/v13122478","article-title":"Immunopathology of RSV: an updated review","volume":"13","author":"Bergeron HC","year":"2021","unstructured":"Bergeron HC, Tripp RA. Immunopathology of RSV: an updated review. Viruses. 2021, 13:10.3390\/v13122478","journal-title":"Viruses"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.114326","article-title":"Respiratory Syncytial Virus in Children: A Comprehensive Review on Publication Trends, Epidemiology, Pathogenesis, Vaccines, and Prevention Strategies","author":"Sreedevi S","year":"2023","unstructured":"Sreedevi S, Krishna G. Respiratory Syncytial Virus in Children: A Comprehensive Review on Publication Trends, Epidemiology, Pathogenesis, Vaccines, and Prevention Strategies. Viral Infectious Diseases Annual Volume 2024. Saxena SK (ed): IntechOpen, London, United Kingdom; 2023. 10.5772\/intechopen.114326"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.64762","article-title":"Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies","volume":"17","author":"Shang Z","year":"2021","unstructured":"Shang Z, Tan S, Ma D. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies. Int J Biol Sci. 2021, 17:4073-91. 10.7150\/ijbs.64762","journal-title":"Int J Biol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li Y","year":"2022","unstructured":"Li Y, Wang X, Blau DM, et al.. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022, 399:2047-64. 10.1016\/S0140-6736(22)00478-0","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16852","article-title":"Pediatric respiratory syncytial virus hospitalizations and respiratory support after the COVID-19 pandemic","volume":"7","author":"Winthrop ZA","year":"2024","unstructured":"Winthrop ZA, Perez JM, Staffa SJ, McManus ML, Duvall MG. Pediatric respiratory syncytial virus hospitalizations and respiratory support after the COVID-19 pandemic. JAMA Netw Open. 2024, 7:e2416852. 10.1001\/jamanetworkopen.2024.16852","journal-title":"JAMA Netw Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.12.23289898","article-title":"Disrupted seasonality and association of COVID-19 with medically attended respiratory syncytial virus infections among young children in the US: January 2010-January 2023","author":"Wang L","year":"2023","unstructured":"Wang L, Davis PB, Berger NA, Kaelber DC, Volkow ND, Xu R. Disrupted seasonality and association of COVID-19 with medically attended respiratory syncytial virus infections among young children in the US: January 2010-January 2023. medRxiv. 2023, 10.1101\/2023.05.12.23289898","journal-title":"medRxiv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003354","article-title":"Landscape of respiratory syncytial virus","volume":"137","author":"Duan Y","year":"2024","unstructured":"Duan Y, Liu Z, Zang N, et al.. Landscape of respiratory syncytial virus. Chin Med J (Engl). 2024, 137:2953-78. 10.1097\/CM9.0000000000003354","journal-title":"Chin Med J (Engl)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073923","article-title":"Recommendations for the prevention of RSV disease in infants and children: policy statement","volume":"156","year":"2025","unstructured":"Recommendations for the prevention of RSV disease in infants and children. policy statement. Pediatrics. 2025, 156:10.1542\/peds.2025-073923","journal-title":"Pediatrics"},{"key":"ref18","unstructured":"Ribavirin tablet, package insert. (2017). Accessed. November 20, 2025: https:\/\/rsc.niaid.nih.gov\/resources\/ribavirin-tablet-package-insert."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313551","article-title":"Ziresovir in hospitalized infants with respiratory syncytial virus infection","volume":"391","author":"Zhao S","year":"2024","unstructured":"Zhao S, Shang Y, Yin Y, et al.. Ziresovir in hospitalized infants with respiratory syncytial virus infection. N Engl J Med. 2024, 391:1096-107. 10.1056\/NEJMoa2313551","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt LL","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, et al.. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022, 386:837-46. 10.1056\/NEJMoa2110275","journal-title":"N Engl J Med"},{"key":"ref21","unstructured":"RSV immunization guidance for infants and young children. (2024). Accessed. November 20, 2025: https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/infants-young-children.html."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin MP","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, et al.. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020, 383:415-25. 10.1056\/NEJMoa1913556","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023","volume":"72","author":"Jones JM","year":"2023","unstructured":"Jones JM, Fleming-Dutra KE, Prill MM, et al.. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023, 72:920-5. 10.15585\/mmwr.mm7234a4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref24","unstructured":"U.S. FDA approves Merck\u2019s ENFLONSIA\u2122 (clesrovimab-cfor) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants born during or entering their first RSV season. (2025). Accessed. November 20, 2025: https:\/\/www.merck.com\/news\/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial...."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.003","article-title":"166. A phase 2b\/3 study to evaluate the efficacy and safety of an investigational respiratory syncytial virus (RSV) antibody, clesrovimab, in healthy preterm and full-term infants","volume":"12","author":"Zar HJ","year":"2025","unstructured":"Zar HJ, Simoes E, Madhi S, et al.. 166. A phase 2b\/3 study to evaluate the efficacy and safety of an investigational respiratory syncytial virus (RSV) antibody, clesrovimab, in healthy preterm and full-term infants. Open Forum Infect Dis. 2025, 12:ofae631.003. 10.1093\/ofid\/ofae631.003","journal-title":"Open Forum Infect Dis"},{"key":"ref26","unstructured":"Palivizumab intramuscular. (2024). Accessed. November 20, 2025: https:\/\/www.medcentral.com\/drugs\/monograph\/16441-398034\/palivizumab-intramuscular."},{"key":"ref27","unstructured":"Beyfortus\u00ae (nirsevimab-alip) efficacy and safety profile overview. (2025). Accessed. November 20, 2025: https:\/\/pro.campus.sanofi\/us\/products\/beyfortus\/pivotal-trials."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham BS","year":"2011","unstructured":"Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev. 2011, 239:149-66. 10.1111\/j.1600-065X.2010.00972.x","journal-title":"Immunol Rev"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12112305","article-title":"Immune responses to respiratory syncytial virus vaccines: advances and challenges","volume":"12","author":"Silva GS","year":"2024","unstructured":"Silva GS, Borges SG, Pozzebon BB, Souza AP. Immune responses to respiratory syncytial virus vaccines: advances and challenges. Microorganisms. 2024, 12:10.3390\/microorganisms12112305","journal-title":"Microorganisms"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12101259","article-title":"Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines","volume":"12","author":"Topalidou X","year":"2023","unstructured":"Topalidou X, Kalergis AM, Papazisis G. Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines. Pathogens. 2023, 12:10.3390\/pathogens12101259","journal-title":"Pathogens"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01001-z","article-title":"Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus","volume":"9","author":"Fuchs J","year":"2024","unstructured":"Fuchs J, H\u00fcbner J, Schmidt A, et al.. Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus. NPJ Vaccines. 2024, 9:205. 10.1038\/s41541-024-01001-z","journal-title":"NPJ Vaccines"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors--friend or foe?","volume":"159","author":"Saxena M","year":"2013","unstructured":"Saxena M, Van TT, Baird FJ, Coloe PJ, Smooker PM. Pre-existing immunity against vaccine vectors--friend or foe?. Microbiology (Reading). 2013, 159:1-11. 10.1099\/mic.0.049601-0","journal-title":"Microbiology (Reading)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons","volume":"78","author":"Ison MG","year":"2024","unstructured":"Ison MG, Papi A, Athan E, et al.. Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis. 2024, 78:1732-44. 10.1093\/cid\/ciae010","journal-title":"Clin Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2315089","article-title":"Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis","volume":"23","author":"San Francisco Ramos A","year":"2024","unstructured":"San Francisco Ramos A, Liu Sanchez C, Bovill Rose T, et al.. Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis. Expert Rev Vaccines. 2024, 23:266-82. 10.1080\/14760584.2024.2315089","journal-title":"Expert Rev Vaccines"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10071450","article-title":"Viral vector vaccine development and application during the COVID-19 pandemic","volume":"10","author":"Deng S","year":"2022","unstructured":"Deng S, Liang H, Chen P, et al.. Viral vector vaccine development and application during the COVID-19 pandemic. Microorganisms. 2022, 10:10.3390\/microorganisms10071450","journal-title":"Microorganisms"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae508","article-title":"Vaccines for use in special populations: immunocompromised hosts","volume":"231","author":"Ison MG","year":"2025","unstructured":"Ison MG. Vaccines for use in special populations: immunocompromised hosts. J Infect Dis. 2025, 231:552-5. 10.1093\/infdis\/jiae508","journal-title":"J Infect Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.05.005","article-title":"Protective and dysregulated T cell immunity in RSV infection","volume":"3","author":"Openshaw PJ","year":"2013","unstructured":"Openshaw PJ, Chiu C. Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol. 2013, 3:468-74. 10.1016\/j.coviro.2013.05.005","journal-title":"Curr Opin Virol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1080\/25310429.2025.2451456","article-title":"Respiratory syncytial virus vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine","volume":"31","author":"Alfaro T","year":"2025","unstructured":"Alfaro T, Froes F, Vicente C, et al.. Respiratory syncytial virus vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine. Pulmonology. 2025, 31:2451456. 10.1080\/25310429.2025.2451456","journal-title":"Pulmonology"},{"key":"ref39","unstructured":"Respiratory syncytial virus (RSV) vaccine safety. (2025). Accessed. November 20, 2025: https:\/\/www.cdc.gov\/vaccine-safety\/vaccines\/rsv.html."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2022.10.003","article-title":"A live single-cycle RSV vaccine expressing prefusion F protein","volume":"577","author":"Lamichhane P","year":"2022","unstructured":"Lamichhane P, Schmidt ME, Terh\u00fcja M, Varga SM, Snider TA, Rostad CA, Oomens AG. A live single-cycle RSV vaccine expressing prefusion F protein. Virology. 2022, 577:51-64. 10.1016\/j.virol.2022.10.003","journal-title":"Virology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2024.105281","article-title":"Short-term immunogenicity of licensed subunit RSV vaccines in residents of long-term care facilities (LTCF) compared to community-dwelling older adults","volume":"25","author":"Falsey AR","year":"2024","unstructured":"Falsey AR, Branche AR, Peasley M, et al.. Short-term immunogenicity of licensed subunit RSV vaccines in residents of long-term care facilities (LTCF) compared to community-dwelling older adults. J Am Med Dir Assoc. 2024, 25:105281. 10.1016\/j.jamda.2024.105281","journal-title":"J Am Med Dir Assoc"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13020097","article-title":"Development, current status, and remaining challenges for respiratory syncytial virus vaccines","volume":"13","author":"Anastassopoulou C","year":"2025","unstructured":"Anastassopoulou C, Medi\u0107 S, Ferous S, Boufidou F, Tsakris A. Development, current status, and remaining challenges for respiratory syncytial virus vaccines. Vaccines (Basel). 2025, 13:10.3390\/vaccines13020097","journal-title":"Vaccines (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/443799-current-and-emerging-strategies-for-the-prevention-of-respiratory-syncytial-virus-rsv-infections-a-comprehensive-review-of-vaccines-and-antibody-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:24:17Z","timestamp":1768220657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/443799-current-and-emerging-strategies-for-the-prevention-of-respiratory-syncytial-virus-rsv-infections-a-comprehensive-review-of-vaccines-and-antibody-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.101340","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}